Skip to main content

Table 1 Baseline characteristics

From: Prevalence of venous obstructions in (recurrent) venous thromboembolism: a case-control study

 

Recurrent VTE

N = 32

No recurrent VTE

N = 24

P-value

Age, years

68.0 (61.3–72.0)

65.0 (45.3–70.8)

0.223

Sex

  

0.298

 - Male

28 (87.5)

18 (75.0)

0.298

 - Female

4 (12.5)

6 (25.0)

0.298

Unprovoked DVT

23 (71.9)

10 (41.7)

0.030

Affected side initial event

  

0.697

 - Left

13 (40.6)

11 (45.8)

0.697

 - Right

19 (59.4)

13 (54.2)

0.697

Affected side recurrent event

 - Ipsilateral (± pulmonary embolism)

17 (53.1)

n/a

–

 - Contralateral (± pulmonary embolism)

9 (28.1)

n/a

–

 - Pulmonary embolism

6 (18.8)

n/a

–

History of pulmonary embolism

8 (25.0)a

4 (16.7)b

0.525

Family history of DVT

10 (31.3)

3 (12.5)

0.122

Antithrombotic therapy

32 (100.0)

17 (70.8)

0.001

Antithrombotic therapy, type

  

0.071

 - VKA

26 (81.3%)

16 (66.7)

0.212

 - DOACc

6 (18.8%)

0 (0.0)

0.035

Elastic compression stockings, use

19 (59.4)

3 (12.5)

< 0.001

  1. Data are n (%) or median (IQR)
  2. DOAC Direct oral anticoagulant, DVT Deep venous thrombosis, LMWH Low Molecular Weight Heparin, n/a Not applicable, VKA Vitamin K Antagonist, VTE Venous Thrombo-Embolism
  3. a All pulmonary embolisms were recurrent VTE which developed after the primary thrombo-embolic event. In 6 patients it presented as a solitary pulmonary embolism and in 2 patients it presented concurrent with a recurrent deep-vein thrombosis
  4. b All pulmonary embolism were concurrent with the primary thrombo-embolic event
  5. c The DOACs used were Rivaroxaban (n = 4), Apixaban (n = 1), and Dabigatran (n = 1)